Navigation Links
InVitria Showcases Cell Culture Productivity Enhancers at BioProcess International
Date:9/12/2008

FORT COLLINS, Colo., Sept. 12 /PRNewswire/ -- InVitria (http://www.InVitria.com), a leading global supplier of animal free products that enhance productivity, safety and time to market for companies in the biopharmaceutical, cell culture, life science research and diagnostics industry, will be an exhibitor and presenter at the BioProcess International Conference and Exhibition in Anaheim, California on September 23-26. (http://www.ibclifesciences.com/B8171/overview.xml)

"This is a major annual event for the bioprocessing industry and we will showcase the productivity improvements our customers have experienced by using our line of cell culture ingredients," said Brandy Sargent, InVitria Account Manager. "Two InVitria products -- Cellastim and Lacromin -- can replace bovine or human sources of albumin or transferrin and provide better productivity, enhanced safety and more consistent results. Our customers have asked for animal free products and products that improve their productivity. InVitria's products deliver on both."

About InVitria (http://www.InVitria.com)

InVitria has developed animal free cell culture ingredients that enhance productivity, safety and time to market for companies in the biopharmaceutical, cell culture, life science research and diagnostics industry. InVitria's animal free product line includes:

-- Cellastim -- Cellastim is an albumin used to replace bovine albumin and

human albumin as a cell culture ingredient and biopharmaceutical

formulation excipient. Cellastim is a recombinant protein and has been

shown to improve mammalian cell culture productivity by up to 50% when

compared with other forms of albumin. Cellastim also has been an

effective component in stem cell media and primary cell media.

(see http://www.Cellastim.com )

-- Lacromin -- Lacromin has been shown to replace bovine transferrin and

human transferrin in cell culture media. In addition, Lacromin is a

strong growth promotant as a cell culture ingredient in mammalian cell

culture media. (see http://www.Lacromin.com )

-- Lysobac -- Lysobac is a bacterial cell lysis agent that is more

efficient and more consistent compared to chicken lysozyme and provides

higher protein yield compared with mechanical cell lysis. Lysobac is

used in bacterial fermentation to improve recombinant protein

yields.(see http://www.Lysobac.com )

For more information about the InVitria line of products, please e-mail info@InVitria.com or call 1-800-916-8311.


'/>"/>
SOURCE InVitria
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Siemens Showcases Its Most Comprehensive and Advanced Breast Care Portfolio
2. ACORN Showcases Oncology CRO, EDC, PRO and Data Warehouse at 44th Annual DIA Meeting
3. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
4. Agriculture Department Warns Consumers of Tainted Raw Milk Sold by Chester County Dairy
5. BD Announces FDA 510(k) Clearance of Two-Hour Test to Identify Superbug in Patients with Positive Blood Cultures
6. Agriculture Department Warns Consumers of Tainted Raw Milk Sold by Lebanon County Dairy
7. AdvanDx Submits Yeast Traffic Light PNA FISH(TM) for FDA 510(k) Clearance for Detection of Candida species in Positive Blood Cultures
8. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. Ozarelix Phase 2 Data Presented at 29th Congress of the Societe Internationale dUrologie
11. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
Breaking Medicine Technology:
(Date:4/28/2017)... ... ... enough sleep affects much more than energy – it also has mental and physical benefits. ... motor reaction time, which can increase the risk of having a car accident. , ... the NSF to help you sleep better and feel better:, , ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... http://www.wiredlifesolutions.com , “Computers are everywhere and they’re here to stay,” said ... Global Climate Change and Your Health on Voice America sponsored by Nature’s Tears® ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The ... board members and officers for 2017-2018. The annual board election process has been in ... a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
(Date:4/28/2017)... Harbor, Md. (PRWEB) , ... April 28, 2017 ... ... Care Association of America (UCAOA) and College of Urgent Care Medicine will host ... 2017 workshops, sessions and speakers will help those in the industry adapt to ...
Breaking Medicine News(10 mins):